RT Journal Article
SR Electronic
T1 Salivary detection of COVID-19. Clinical performance of oral sponge sampling for SARS-CoV-2 testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.17.21251556
DO 10.1101/2021.02.17.21251556
A1 Marquette, Charles Hugo
A1 Boutros, Jacques
A1 Benzaquen, Jonathan
A1 Ilié, Marius
A1 Labaky, Mickelina
A1 Benchetrit, Didier
A1 Lavrut, Thibaut
A1 Leroy, Sylvie
A1 Chemla, Richard
A1 Carles, Michel
A1 Tanga, Virginie
A1 Maniel, Charlotte
A1 Bordone, Olivier
A1 Allégra, Maryline
A1 Lespinet, Virginie
A1 Fayada, Julien
A1 Griffonnet, Jennifer
A1 Hofman, Véronique
A1 Hofman, Paul
YR 2021
UL http://medrxiv.org/content/early/2021/05/10/2021.02.17.21251556.abstract
AB Background The current diagnostic standard for coronavirus 2019 disease (COVID-19) is reverse transcriptase-polymerase chain reaction (RT-PCR) testing with naso-pharyngeal (NP) swabs. The invasiveness and need for trained personnel make the NP technique unsuited for repeated community-based mass screening. We developed a technique to collect saliva in a simple and easy way with the sponges that are usually used for tamponade of epistaxis. This study was carried out to validate the clinical performance of oral sponge (OS) sampling for SARS-CoV-2 testing.Methods Over a period of 22 weeks, we collected prospectively 409 paired NP and OS samples from consecutive subjects presenting to a public community-based free screening center. Subjects were referred by their attending physician because of recent COVID-19 symptoms (n=147) or by the contact tracing staff of the French public health insurance since they were considered as close contacts of a laboratory-confirmed COVID-19 case (n=262).Results In symptomatic subjects, RT-PCR SARS-CoV-2 testing with OS showed a 96.5% (95%CI: 89.6-94.8) concordance with NP testing, and, a 93.3% [95%CI: 89.1-97.3] sensitivity. In close contacts the NP-OS concordance (93.8% [95%CI: 90.9-96.7]) and OS sensitivity (71.9% [95%CI: 66.5-77.3]) were slightly lower.Conclusion These results strongly suggest that OS testing is a straightforward, low-cost and high-throughput sampling method that can be used for frequent RT-PCR testing of COVID-19 patients and mass screening of populations.Summary of the “take home” message OS sampling for SARS-CoV2 RT-PCR is an easy to perform, straightforward self-administered sampling technique, which has a sensitivity of up to 93.3% in symptomatic patients and 71% in close contact subjects.Competing Interest StatementPaul Hofman is a member of the scientific advisory board (group of european experts) of Biocartis. However, this boad is totally independ of BiocartisClinical TrialNCT04418206Funding StatementThis work was supported by Conseil Departemental 06, Ville de Nice, Metropole Nice Cote d'Azur, Fonds de Dotation AVENI, and from private donators. Acknowledgements: Special thanks to E. Faidhi, N. Fridlyand, A. Rauscher, E. Maris, the Lauro family and to the many private donators for their generous contribution. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The promoter of the study was the Center Hospitalier Universitaire de Nice. The agreement for the study of the Institutional review board Sud Mediterranee V was obtained on April 22, 2020 (registration # 20.04014.35208). SHAM liability insurance (n 159087). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in this manuscript can be available after contacting the corresponding author